^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer

Excerpt:
Ceritinib has demonstrated impressive activity in the clinic in crizotinib-resistance patients...These findings are consistent with preclinical studies presented in this manuscript demonstrating the activity of ceritinib against G1269A and S1206Y crizotinib-resistance mutations, and its lack of potency against the G1202R mutation.
DOI:
10.1158/2159-8290.CD-13-0846